Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02944565 · FLOW

Participant flow

Daratumumab in Treating Patients With Multiple Myeloma · Source last updated 2019-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Daratumumab)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients were enrolled beginning in February 2017 and patient enrollment was completed in June 2017
Complete source fields
groups
  1. description
    Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Daratumumab)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients were enrolled beginning in February 2017 and patient enrollment was completed in June 2017

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice